ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1222

Suppressive Effect of Butyrate on Monosodium Urate (MSU) Crystal-Induced IL-1beta Production Is Mediated Via Inhibition of Class I Histone Deacetylases

Maartje Cleophas1, Tania Crisan2, Heidi Lemmers3, Helga Toenhake-Dijkstra2, Gianluca Fossati4, Tim Jansen5, Charles Dinarello6, Mihai Netea2 and Leo Joosten2, 1Internal Medicine, Radboud Unversity Medical Center, Nijmegen, Netherlands, 2Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 3Internal Medicine, Radboud Univeristy Medical Center, Nijmegen, Netherlands, 4Department of Preclinical Research and Development, Italfarmaco, Cinisello Balsamo, Italy, 5Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 6Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: gout and histone acetylation, IL-1

  • Tweet
  • Email
  • Print
Session Information

Title: Metabolic and Crystal Arthropathies: Mechanisms of Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose

Gouty arthritis is triggered by endogenously formed monosodium urate (MSU) crystals. MSU crystals alone are unable to induce cytokine production and therefore a second stimulus is needed to induce the release of active interleukin (IL)-1β, the dominant cytokine in acute gout. Toll-like receptor (TLR) ligands such as LPS or saturated free fatty acids (FFA) can provide such a second signal and stimulate transcription of pro-IL-1β. In contrast to FFA, which can act as second signal for MSU-mediated cytokine production, the short-chain fatty acid butyrate has many anti-inflammatory effects. One of the possible mechanisms involved is inhibition of histone deacetylases (HDACs). Here, we explored the effects of butyrate on MSU/FFA-induced cytokine production and its inhibition of several specific HDACs.

Methods

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors or gouty arthritis patients and stimulated for 24 hours with MSU and palmitic acid (C16.0) in the presence or absence of butyrate or the synthetic HDAC inhibitors. Cytokine responses were measured with specific ELISAs and quantitative PCR. Effects on HDAC activity were measured with a fluorimetric cellular assay kit.

Results

Butyrate decreased C16.0/MSU-induced production of IL-1b, IL-6, and IL-8, as well as the transcription of IL-1b mRNA. Similar results were obtained when PBMCs isolated from gout patients were exposed to butyrate and C16.0/MSU. Butyrate selectively inhibited class I HDACs, but the strongest inhibition was found for HDAC8. However, the selective HDAC8 inhibitor ITF-A did not decrease ex-vivo C16.0/MSU-induced IL-1b production. The pan HDAC inhibitor Panobinostat and the HDAC inhibitor ITF-B significantly decreased C16.0/MSU-induced IL-1b production. Interestingly, the dose-response curves of butyrate and ITF-B are very different between PBMC’s stimulated with C16.0/MSU or with LPS.

Conclusion

Butyrate and ITF-B have in common that they both inhibit class I HDACs and potently inhibit C16.0/MSU-induced IL-1b production. ITF-B also inhibits HDAC10 and -11, but the effect on C16.0/MSU- and LPS-induced IL-1b production is strikingly similar to that of butyrate. Therefore we conclude that the effect of butyrate on C16.0/MSU-induced cytokine production is mediated through class I HDAC inhibition. In contrast to the high concentrations of butyrate needed for cytokine suppression, synthetic HDAC inhibitors show potent anti-inflammatory effects at low concentrations. These novel HDAC inhibitors could be effective in the treatment of acute gout. Moreover, the use of specific HDAC inhibitors could even improve the efficacy and reduce any potential adverse effects.


Disclosure:

M. Cleophas,
None;

T. Crisan,
None;

H. Lemmers,
None;

H. Toenhake-Dijkstra,
None;

G. Fossati,
None;

T. Jansen,

Abbvie,

2,

UCB,

2,

Abbvie,

5,

AstraZeneca,

5,

UMS,

5,

Janssen Pharmaceutica Product, L.P.,

5,

Menarini,

5,

Novartis Pharmaceutical Corporation,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

Abbvie,

8;

C. Dinarello,
None;

M. Netea,
None;

L. Joosten,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suppressive-effect-of-butyrate-on-monosodium-urate-msu-crystal-induced-il-1beta-production-is-mediated-via-inhibition-of-class-i-histone-deacetylases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology